Clincosm LogoSign in Get a demo

Association of Centre of Excellence Self- Administered Questionnaire Score and Frailty Levels

Sponsor
Jewish General Hospital (Other)
Overall Status
Active, not recruiting
CT.gov ID
NCT03991806
Collaborator
(none)
30,000
Enrollment
1
Location
51
Anticipated Duration (Months)
588
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

This study evaluates the frailty and the health adverse events in the population of the Canadian Longitudinal Study on Aging. It will be used the Centre of Excellence Self-Administered questionnaire (CESAM) which assesses frailty of older adults by providing a score and a of frailty in 4 levels.

Condition or Disease Intervention/Treatment Phase
  • Other: Obsservational

Detailed Description

Age is broadly recognized to confer a risk for health adverse outcomes, but it is an insensitive and non-specific measure for use in individual decision-making. Frailty has been emerging to take its rightful place as a better measure for over past decades. Despite general consensus that the concept of frailty is clinically useful, the lack of agreement on its definition and the challenge of its measurement by front-line health providers mean that frailty remains only 'their apparent' to chronological age as a criterion to select older persons at risk.

Study Design

Study Type:
Observational
Anticipated Enrollment :
30000 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Association of Centre of Excellence Self-Administered Questionnaire (CESAM) Score and Frailty Levels With Incident Health Adverse Events in Older Community Dwellers: Results of the Canadian Longitudinal Study on Aging
Actual Study Start Date :
May 31, 2020
Anticipated Primary Completion Date :
Dec 31, 2023
Anticipated Study Completion Date :
Aug 31, 2024

Outcome Measures

Primary Outcome Measures

  1. Dementia [around 18 months]

    The algorithm is a three- step process involving administration of the neuropsychological battery to develop composite score in the three domains-memory, executive function, and psychomotor speed. The primary outcome of the study will be to determine the number of participants to whom the memory, the executive function, and the psychomotor speed are affected.

Secondary Outcome Measures

  1. Medication [around 18 months]

    In the maintaining contact interview, one question will be asked of all participants in relation to prescription medication use in the preceding month. A second question asks about the frequency of prescription drug use during this month. The secondary outcome of the study will be to determine the number of the medication that the participant take during a period of time.

Eligibility Criteria

Criteria

Ages Eligible for Study:
65 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:

  • Being 65 years and over

  • Being enrolled in the Canadian Longitudinal Study on Aging

Exclusion Criteria:

  • Never being enrolled in the Canadian Longitudinal Study on Aging

  • Undisclosed health adverse events

Contacts and Locations

Locations

Site City State Country Postal Code
1 Jewish General Hospital Montréal Quebec Canada H3T 1E2

Sponsors and Collaborators

  • Jewish General Hospital

Investigators

  • Principal Investigator: Olivier Beauchet, MD, Jewish General Hospital

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Olivier Beauchet, MD, Professor of Geriatrics, Jewish General Hospital
ClinicalTrials.gov Identifier:
NCT03991806
Other Study ID Numbers:
  • 2020-1844
First Posted:
Jun 19, 2019
Last Update Posted:
Mar 29, 2022
Last Verified:
Mar 1, 2022
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:
Frailty
Wounds and Injuries
Cognitive Dysfunction

Study Results

No Results Posted as of Mar 29, 2022